Drug Trial Radar · NCT06586112
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
912
Actual
Start
Jul 25, 2024
Primary completion
Sep 19, 2025
Study completion Nov 20, 2025
Sponsor
- Lead sponsor
- Alumis IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.
Conditions
- Plaque Psoriasis
Interventions
EnvudeucitinibDrug
ESK-001
ApremilastDrug
Apremilast
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placeboTime frame: 16 weeks
Locations
156 sites in 10 countries. Site status is shown where the registry gives one.
Alliance Dermatology
Phoenix, Arizona
Scottsdale Clinical Trials
Scottsdale, Arizona
Northwest Arkansas Clinical Trials Center (NWACTC), PLLC
Rogers, Arkansas
Exalt Clinical Research
Chula Vista, California
California Dermatology & Clinical Research Institute
Encinitas, California
First OC Dermatology Research Inc
Fountain Valley, California
Marvel Clinical Research, LLC
Huntington Beach, California
Sunwise Clinical Research, LLC
Lafayette, California
Wallace Medical Group Inc
Los Angeles, California
Northridge Clinical Trials - Elite Clinical Network
Northridge, California
Pasadena Clinical Trials
Pasadena, California
Therapeutics Clinical Research
San Diego, California
Unison Clinical Trials/ Shahram Jacobs MD
Sherman Oaks, California
Olive View - UCLA Education & Research Institute
Sylmar, California
California Dermatology Institute - Thousand Oaks
Thousand Oaks, California
Clearlyderm Dermatology - West Boca Raton
Boca Raton, Florida
Driven Clinical Research
Coral Gables, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Glick Skin Institute - Margate
Margate, Florida
San Marcus Research Clinic, Inc - Miami
Miami Lakes, Florida
Savin Medical Group LLC
Miami Lakes, Florida
Oceanic Research Group
North Miami Beach, Florida
LENUS Research
Sweetwater, Florida
Caban Skin Institute
Tampa, Florida
ForCare Medical Center
Tampa, Florida
Skin Care Physicians of Georgia - Warner Robins
Macon, Georgia
MetroMed Clinical Trials
Chicago, Illinois
Arlington Dermatology
Rolling Meadows, Illinois
NorthShore Medical Group - Dermatology - Skokie
Skokie, Illinois
Dundee Dermatology
West Dundee, Illinois
Dawes Fretzin Clinical Research Group
Columbus, Indiana
The South Bend Clinic
South Bend, Indiana
Equity Medical - Bowling Green
Bowling Green, Kentucky
Velocity Clinical Research at The Dermatology Clinic, Baton Rouge
Baton Rouge, Louisiana
Tulane University School of Medicine
New Orleans, Louisiana
MetroBoston Clinical Partners
Brighton, Massachusetts
Cleaver Dermatology
Kirksville, Missouri
OptiSkin
New York, New York
The Ohio State University Wexner Medical Center (OSUWMC) - OSU Dermatology East - Columbus
Gahanna, Ohio
Dermatologists of Southwestern Ohio, LLC
Mason, Ohio
Showing 40 of 156 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.